Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in EGFR TKI-resistant lung adenocarcinoma
NCT01718847Phase 2Completed
- Sponsor
- National OncoVenture
- Start
- Jan 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in lung adenocarcinoma, sponsored by National OncoVenture. Started Jan 2013; status: completed.
02
Drugs
poziotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01718847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718847.